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economic burden of stroke was estimated from a societal perspective with an 
incidence approach.Data were collected from clinical registries and 100 patients 
were included. In the cost calculations, both direct and indirect costs were esti-
mated. Results: Men (78%) consumed more acute care in hospitals, than the 
women (22%). Younger patients (59%) brought a significantly higher burden on 
society compared with the older patients due to the loss of productivity and the 
increased use of resources in health care.41% of patients who have hypertension 
and 45% of patients with alcohol and smoking habits have more prone to stroke 
rather than the patients with other habits and comorbidities.56% of patients have 
the hospital stay of 5-10 days and 52% are using 4-7 medicines per day. From 
the study results ,average direct medical costs and direct nonmedical costs and 
Indirect costs were found to be 2819 ,705 and 754 rupees. In essence, majority of 
the costs for stroke care fall on the hospital,than the long-time care and informal 
care costs and productivity loss. ConClusions: The result of this study can be 
used for further development of the methods for economic analyses as well as for 
analysis of improvements and investments in health care. This aspect highlights 
the enormous importance, for our healthcare service, to invest more in preven-
tion. This cost analysis highlights the importance of clinical pharmacist to set up 
significant prevention programs on selected,high-risk population to reduce the 
economic burden of stroke, which is mostly attributable to hospital and inpatient 
rehabilitation costs immediately after the acute episode.
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objeCtives: To review the direct patient-level costs of selected cardiovascular 
events (CVEs): unstable angina, myocardial infarction (MI), cardiac revasculariza-
tion, heart failure, ischemic stroke, acute coronary syndrome in Europe. Methods: 
A systematic literature review was conducted for the period between January 
2000 and March 2015. MEDLINE, EMBASE, ECONLIT, and NHS Economic Evaluation 
Database, conference abstracts from the American Heart Association, American 
College of Cardiology, European Society of Cardiology, European Atherosclerosis 
Society, International Society of the Pharmacoeconomics and Outcomes Research 
and relevant reference lists were searched to identify published articles reporting 
direct costs of one or more CVEs (angina, myocardial infarction, cardiac revas-
cularization, heart failure, ischemic stroke, acute coronary syndrome) in Europe 
(United Kingdom, Germany, Spain, France, Italy, Denmark, Finland, Iceland, 
Norway, Sweden, Belgium, Switzerland, The Netherlands). Two reviewers indepen-
dently assessed studies against inclusion criteria and abstracted cost estimates; 
discrepancies were resolved through discussion or by third reviewer. Studies were 
included if they reported patient-level direct medical costs of one or more CVE(s) 
from a primary economic analysis or cost-effectiveness model among adults with 
identified dyslipidemia or elevated Low Density Lipoprotein-Cholesterol. Costs as 
reported in each study were inflated to 2015 values. Results: Forty-eight studies 
were included for abstraction. Cost estimates for at least one event were found 
in twelve of the thirteen specified countries listed in the search strategy. Annual 
costs of care were highest for stroke (€ 958-€ 10,334), revascularization procedures 
(€ 211-€ 12,383) and MI (€ 558-€ 17,262). The highest cost acute events were revas-
cularization procedures, specifically CABG (€ 10,814- € 25,587), and ischemic stroke 
(€ 3,686-€ 7,978); angina (€ 935-€ 5,214) and heart failure (€ 1,106-€ 4,905) acute costs 
were relatively lower than other conditions. ConClusions: The findings of this 
study highlight the wide variation in the sources and populations used to populate 
economic models in the literature and the substantial costs of CVEs despite event 
type or country of origin.
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objeCtives: The aim is to assess for 2012 the direct and non-directly cost of dia-
betes from a public payer perspective using a new (bottom-up) method and the 
French health insurance medico-administrative database (SNIIRAM). Methods: 
Using information about 60 millions of individuals from the general scheme insur-
ance database (86% of the 69 million individuals insured by all French insurance 
schemes,), we identified people who received care for diabetes if they had an 
ICD-10 diagnosis for diabetes as a long-term chronic disease or at least 3 annual 
reimbursements for anti-diabetic drugs. Costs of all reimbursed expenditures (out-
patient/inpatient care, disability/sickness benefits) were extracted per individual. 
To estimate the burden of diabetes, we identified expenditure items which were 
directly attributable to diabetes (anti-diabetic drugs, medical devices, hospitaliza-
tion with an ICD diabetes code). For other expenditures, we used an incremental 
approach and also econometric model by estimating the additional cost due to 
diabetes (by age and gender) between the diabetic and the non-diabetic popula-
tion. Results: Among 69 million individuals insured by all insurance schemes, 3.3 
million (5%) had diabetes. The overall diabetic population expenditure accounted for 
22 billion, 15% (of the total expenditures reimbursed by the national health insur-
ance). Overall, 11.4 billion (52%) euros were considered as related to diabetes care. 
Reimbursements directly attributable to diabetes accounted for 2.6 billion (23% of 
the 11.4 billion euros) and other costs, mostly related to complications, for 8.8 billion 
(77%). Inpatient care represented the main part of the overall cost of diabetes care 
(22%) together with drugs (20%) and medical auxiliaries (15%). ConClusions: Care 
for diabetes complications and additional treatments for diabetic people account 
for the highest part of the costs of diabetes care. The prevention of acute illness 
separate models to calculate cost of illness for each selected diseases. Medical 
resources included hospital stays, outpatient visits, ambulance service and reha-
bilitation. Results: Obesity-related and overweight-related expenses incurred by 
the state for treatment and management of patients were amounted to 10.2 billion 
rubles ($ 190.5 million) for stroke, 7.6 billion rubles ($ 141.9 million) for heart attack 
and 346.3 billion rubles ($ 6.5 billion) for diabetes mellitus. ConClusions: Obesity 
and overweight associated with significant economic burden on Russia’s health care 
system. There is a striking direct relationship between the cost of care on stroke, 
heart attack, diabetes mellitus and obesity and overweight that leading to increasing 
significant economic and social losses.
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objeCtives: The prevalence of atrial fibrillation (AF), a common form of car-
diac arrhythmia, is rapidly rising in the developed world. Though several studies 
addressed the cost of illness, recent improvements in the disease management 
may have affected per capita medical resources consumption and costs, there-
fore it is desirable to provide updated estimates. This naturalistic study aimed at 
estimating costs and resource consumption related to AF from the perspective of 
the Italian Healthcare System in a large cohort of hospitalized cases. Methods: 
Using healthcare administrative databases (HADB) of Lombardy, a region in 
Northern Italy (10 million dwellers), we identified the cohort of residents who 
underwent a first hospitalization with a diagnosis of AF between 2003 and 2009, 
after a wash-out period of 3 years. We followed them until 2010, death or emi-
gration, extracting from HADB information on hospitalizations, drug prescrip-
tions and outpatient visits with related direct costs. We estimated mean annual 
resources consumption per 100 subjects and mean annual per capita cost through 
the Bang and Tsiatis approach. Results: We recruited a cohort of 143,022 sub-
jects (49% males), with a mean age of 75 years (±12 standard deviation) and a 
mean survival time of 5 years (95% confidence interval (CI): 5.0; 5.1) from baseline. 
Mean annual per-capita expenditure was 4,008€ (95%CI: 3,981; 4,039), of which 
65.2% was absorbed by hospitalizations, 18.5% by drug prescriptions and 16.3% 
by outpatient visits. We estimated 84.7 hospital admissions, the main driver of 
costs, per 100 subjects per year (95%CI: 83.8; 85.6), of which 17.0 (95%CI: 16.8; 
17.2) with an AF diagnosis. ConClusions: In line with literature, our results 
highlighted a high burden of AF, with large per capita healthcare expenditures 
and a high number of hospitalizations. Since AF has been described as an epi-
demic, increased attention should be devoted to the management of such 
disease.
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objeCtives: To estimate direct medical costs of cardiovascular (CV) events in the 
UK: myocardial infarction (MI), ischemic stroke (IS), heart failure (HF), transient 
ischemic attack (TIA), unstable angina (UA), and revascularisation. Methods: We 
used 2006-2012 Clinical Practice Research Datalink and Hospital Episode Statistics 
data to identify individuals with their first and, if present, repeated CV-related 
hospitalisations. Patients > 18 years receiving lipid-modifying therapy within 180 
days before the CV event were followed for 36 months, death, or loss to follow 
up. Patients were classified as CV Low/Moderate Risk, CV High Risk and CV Event 
History. Baseline (12 months before first CV event), acute (first 6 months after-
ward) and long-term costs (subsequent 30 months, annualised) were estimated 
by applying 2014 UK costs to drugs, hospitalisations and visits. Incremental CV 
event-related costs were calculated as the difference from baseline, reporting means 
across all cohorts and ranking cohort-specific means. Results: There were 6,408 
patients in CV Low/Moderate Risk, 17,685 in the CV High Risk, and 5,274 in CV Event 
History cohorts. Across the three cohorts, mean incremental acute CV event costs 
for revascularisation were £5,669 (£5,468-£5,823), MI £4,277 (£3,707-4,573), IS £3638 
(£3,472-4,572), HF £2,635 (£ 2390-£3461), UA £2,229 (£2063-£2489) and TIA £1,572 
(£1441-£1814). Mean incremental long-term costs were as follows: HF £1,129 (-£37-
£2829), MI £959 (£515-£1385), IS £953 (£682-£1072), TIA £793 (£340-£1692), UA £373 
(£319-£677), and revascularisation -£221 (-£411-£599). Costs of CV Low/Moderate Risk 
cohort ranked the lowest; costs of CV Event History were the highest. Hospitalisation 
costs were the primary drivers for both periods. ConClusions: Revascularisation 
and MI are the costliest CV events. The costs are the highest in the acute phase dur-
ing the first 6 months after a CV event and generally remain higher compared with 
pre-event period. Using real-world evidence, the economic burden of CV patients 
in the UK is substantial.
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eStimating tHe eCOnOmiC BurDen Of StrOke in SOutH inDia :  
a COSt-Of-iLLneSS StuDy
Mounica B
chalapathi, guntur, India
objeCtives: The recently-observed trend towards the stroke patients in raises 
the economic concerns. Cost-of-illness (COI) analysis is the main method of 
providing an overall view on the economic impact of a disease. the main objec-
tive of this study is to estimate the economic burden of stroke. Methods: The 
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were very scarce. Patients were distributed across SOI categories as follows: 3.9% 
mild, 51.8% moderate, 26.4% major, 17.9% severe with LOS 5.61, 10.78, 19.43 and 
34.60 days respectively. Costs for drugs ranged from € 139.82 in SOI1, € 150.26 in SOI2, 
€ 349.51 in SOI3 and € 758.41 in SOI4. Data on clinical biology amounted to € 17.13 per 
patient; on average 15 types of lab tests were used. Costs for imaging also varied 
by severity and were € 876.58, € 866.29, € 930.07 and € 1,247.45 for increasing levels of 
SOI. In total 39 different imaging tests were used covering among others functional 
measurements, radiology, Rx, CT and MRI. Total costs amounted to € 3,653 , € 5,583 , 
€ 9,489 , € 16,660 respectively. Compared to the national average these costs are 5% 
lower, mainly due to underestimation of honoraria. ConClusions: In-hospital 
costs increase with stroke severity, with the most severe patients costing 4.5 times 
more than mild patients. Bottom-up costing approximated the top-down costs.
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an ePiDemiOLOgiCaL eVaLuatiOn Of tHe inCiDenCe Of DeeP VenOuS 
tHrOmBOSiS anD PuLmOnary emBOLiSm in PatientS witH HiP Or knee 
rePLaCement Surgery anD Of itS imPaCt On tHe aVerage LengtH Of 
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objeCtives: Various published sources report an incidence of symptomatic deep 
venous thrombosis (DVT) and pulmonary embolism (PE) in patients undergoing hip 
or knee replacement ranging between 0.3 and 2%. This study aimed at assessing the 
in-hospital incidence of DVT/PE after major orthopaedic surgery in Belgium and the 
impact of these complications on the length of stay and hospitalization costs using 
retrospective data. Methods: The incidence of DVT/PE, the average hospitalization 
cost and the average length of stay (LOS) among patients hospitalized for hip or knee 
replacement surgery were estimated using the longitudinal IMS Hospital Disease 
Database (year 2013), including data (diagnoses, procedures, costs) on 24% of Belgian 
hospital beds. Stays were searched based on ICD-9-CM codes corresponding to hip 
replacement (81.51-81.52-81.53) and knee replacement (81.54-81.55). Occurrence 
of DVT/PE was identified with ICD-9 codes 451.1-451.2-453.4. The impact of a DVT/ 
PE complication on LOS/ cost was assessed through Wilcoxon non-parametrical 
tests. Results: 7,160 stays with hip replacement and 6,223 stays with knee replacement 
were retrieved in the database. The number of stays with a DVT/PE episode was 
respectively equal to 22 and 43 within the two subgroups, resulting in an incidence 
of 0.31% in patients with hip replacement and 0.69% in patients with knee replace-
ment. LOS of patients with a DVT/PE episode was more than twice as high after both 
hip (35.8 vs. 13.59 days; p< 0.001) and knee (31.2 vs. 9.9 days; p< 0.001) replacement. 
Hospitalization costs were also more than doubled in case of DVT/PE complication 
(€ 25,557 vs. € 12,721 in hip replacement; € 24,953 vs. € 11,298 in knee replacement; 
p< 0.001 in both cases). ConClusions: The incidences of symptomatic DVT and 
PE reported in the literature could be confirmed based on this retrospective search. 
The occurrence of DVT/PE increases dramatically both LOS and hospitalization costs 
in patients undergoing hip or knee surgery.
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objeCtives: Stroke is the second leading cause of death globally and the survivors 
are faced with long-term disability. Stroke survivors are also under the risk of recur-
rent strokes causing a potential burden on health care systems. Therefore, cost of 
stroke studies are of special importance to healthcare policy makers in order to 
predict and take precautions for stroke in their health care system. The aim of this 
study was to determine the direct economic cost of stroke from the payer perspec-
tive in Turkey. Methods: A multi-dimensional approach was used to estimate the 
direct costs of stroke in Turkey. First a large dataset covering 5 years data for 2000 
emergency department stroke admissions from a university hospital was analyzed. 
The data set covered information on the severity of the disease, socioeconomic 
status of the patients and also the medical procedures applied during the hospital 
stay. Second, the actual invoices of the same patients hospitalized in 2014 were 
analyzed. Third, a form was designed to explore the treatment strategies, medical 
procedures and resource requirements of stroke outpatients and inpatients. The 
form was applied to an expert panel and the resources determined by the panel 
were priced by the Social Security Institution’s official price list. Results: According 
to the expert panel part of the study, annual outpatient and monitoring costs were 
1.807,58 TL and intensive care and inpatient costs were 5.636,52 TL. The total annual 
cost of stroke per patient was calculated as 7.444,11 TL in Turkey. ConClusions: 
The study showed that stroke treatment had a significant economic burden on the 
healthcare budget. Outpatient and monitoring costs constituted %24 of total costs 
whereas inpatient costs constituted %76 of total costs.
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objeCtives: Venous thromboembolism (VTE) is a common disorder, with about 1 
per 1,000 people per year in the general population.Approximately two-thirds of 
cases of VTE present as deep vein thrombosis (DVT), the formation of a thrombus 
in a deep vein, usually of the lower limbs. Around one third of VTE cases present as 
pulmonary embolism (PE), occurring when dislodged thrombi (from a DVT) travel 
to the lungs. PE can cause sudden death and those who survive an episode occa-
sionally require intensive care, with recovery taking several weeks or months. The 
episodes involving inpatient care and complications could lower substantially the 
burden of diabetes.
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reaL wOrLD eViDenCe anD COStS Of CHrOniC Heart faiLure: finDingS 
frOm 41,413 PatientS Of tHe arnO DataBaSe
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objeCtives: Patients with chronic heart failure (HF) in controlled trials do not 
fully represent real population followed in clinical practice. We wanted to give real 
world picture of epidemiology and hospitalization caractheristics of patients with 
HF, by analyzing administrative database of nearly 2,500,000 subjects. Evaluation 
of healthcare related costs over 1 year follow-up was performed. Methods: Data 
come from ARNO database that includes in-habitants of 7 Local Health Authorities 
of the Italian National Health Service (NHS). Patients were selected when admis-
sion for HF occurred over period of 5 years ( January 1, 2008 to December 31 2012). 
To confirm diagnosis, all patients discharged alive should be prescribed typical 
treatment for HF. Clinical characteristics co-morbidities, treatment, need for re-
hospitalization and mortality occurring in the 1st year following discharge were 
analyzed. Total costs for NHS were calculated as hospitalizations, treatments 
and out-of-hospital speciality visits or examinations. Results: 54,059 patients 
(2.2%) were admitted for HF. The great majority was admitted in Internal Medicine/
Geriatric Departments (69.5%). Of 54,059 patients, 41,413 were discharged alive and 
prescribed HF treatments. Need for re-hospitalization occurred frequently: 56.6% 
of patients was admitted at least once in 1-year following discharge, cardiovas-
cular admissions accounted for just 51% of the total hospitalizations. All-cause 1 
year mortality was 18.9%. Patient with HF generate a cost per year to NHS 7,429€ 
(11,867€ if first admission included). Cost per year were as follows: new hospitali-
zations 76%, drug prescriptions 16%, visits/examinations 8%. ConClusions: Real 
world evidence in HF provides findings different from randomized clinical trials. 
Patients are older and more frequently females. Rate of use of treatments is not 
optimal. All-cause mortality remains high and re-hospitalizations are frequent. 
In nearly half cases, re-hospitalizations are due to non CV reasons, documenting 
relevant role of advanced age and co-morbidities. Costs for NHS are mainly driven 
by hospital costs.
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objeCtives: Atrial Fibrillation (AF) is the most common arrhythmia in Europe. AF 
increases the risk of death and cost of care, and is the second leading risk factor 
for stroke. The study objective was to estimate healthcare resource utilization 
(HCRU) and treatment costs of non-valvular AF (NVAF) patients with and without 
stroke. Methods: Retrospective cohort study of patients newly diagnosed with 
NVAF from January 2003 to December 2013. Patients were identified using medical 
diagnoses (ICD-9 codes) and treatment prescriptions (ATC codes) in the Badalona 
Serveis Assistencials database. HCRU included overall hospital admissions, out-
patient consultations, home-based care, laboratory tests, and pharmacological 
treatments. Differences in annualized total cost rates (95% CIs) per patient were 
calculated in € (2014 tariffs) by estimating HCRU in propensity-score matched 
cohorts of NVAF patients with and without stroke. Results: Overall, 3,052 
patients with NVAF were identified in the study period, and 11.2% had at least one 
stroke event after NVAF diagnosis. Median follow-up time of patients with stroke 
was 519 days. In the first year after stroke, there was on average an incremental 
0.9 hospital admissions per patient, 0.9 additional ER admissions, 2.9 additional 
hospital outpatient consultations, 5.7 additional consultations at other sites, 4.2 
additional procedures/laboratory tests, and 265 additional DDDs of anticoagulant. 
The incremental total cost of stroke per patient was 12,085€ (12,069-12,101) in the 
first year, and 6,384€ (6,377-6,391) for the entire follow-up period. Total cost of 
stroke per patient was 4.4 times higher than non-stroke patients during the first 
year after stroke, and 2.9 times higher for the entire follow-up. ConClusions: 
In Spain, NVAF patients with stroke consumed additional HCRU and treatment 
costs compared to patients without stroke. The burden of stroke was particularly 
important in the first year after stroke, and hospitalizations were the main drivers 
of the increased HCRU and costs.
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objeCtives: To investigate the resources used by ischemic stroke patients when 
hospitalized, and examine this relationship by stroke severity. Comparing a bot-
tom-up costing approach with national top-down costs. Methods: Data from five 
Belgian hospitals were requested for the years 2008 up to 2011 detailing the length-
of-stay (LOS), drugs, medical imaging and clinical biology tests. Participating hospi-
tals were distributed across the country and included regional as well as teaching 
hospitals. Severity of the stroke was defined as mild, moderate, major or severe 
according to the Severity-of-Illness (SOI) categorization within APR-DRG category 
045, which is determined by the classification of primary and secondary diagnoses. 
Average bottom-up costs were compared to the national reimbursement received 
by hospitals. Results: 2,496 hospital admissions were included in our analysis; all 
admissions contributed to the LOS calculations, 2,364 observations were available 
for medical imaging, 1,954 for drug treatments whereas data for clinical biology 
